Bicycle Therapeutics Plc ADR’s recent filing unveils that its Director BAKER BROS. ADVISORS LP acquired Company’s shares for reported $13.56 million on Dec 13 ’24. In the deal valued at $13.76 per share,985,397 shares were bought. As a result of this transaction, BAKER BROS. ADVISORS LP now holds 9,537,643 shares worth roughly $144.4 million.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Then, BAKER BROS. ADVISORS LP bought 500,000 shares, generating $7,670,900 in total proceeds. Upon buying the shares at $15.34, the Director now owns 9,995,274 shares.
Before that, Thompson Travis Alvin sold 6,256 shares. Bicycle Therapeutics Plc ADR shares valued at $157,114 were divested by the CHIEF ACCOUNTING OFFICER at a price of $25.11 per share. As a result of the transaction, Thompson Travis Alvin now holds 19,241 shares, worth roughly $0.29 million.
Stephens initiated its Bicycle Therapeutics Plc ADR [BCYC] rating to an Equal-weight in a research note published on November 08, 2024; the price target was $25. A number of analysts have revised their coverage, including RBC Capital Mkts’s analysts, who began to cover the stock in early September with a ‘”an Outperform”‘ rating. B. Riley Securities also remained covering BCYC and has decreased its forecast on August 07, 2024 with a “Neutral” recommendation from previously “Buy” rating. B. Riley Securities revised its rating on September 11, 2023. It rated BCYC as “a Buy” which previously was an “a Neutral”.
Price Performance Review of BCYC
On Tuesday, Bicycle Therapeutics Plc ADR [NASDAQ:BCYC] saw its stock jump 0.13% to $15.14. Over the last five days, the stock has lost -27.42%. Bicycle Therapeutics Plc ADR shares have fallen nearly -16.26% since the year began. Nevertheless, the stocks have fallen -13.54% over the past one year. While a 52-week high of $28.67 was reached on 10/16/24, a 52-week low of $12.17 was recorded on 12/13/24. SMA at 50 days reached $22.51, while 200 days put it at $22.93.
Levels Of Support And Resistance For BCYC Stock
The 24-hour chart illustrates a support level at 14.78, which if violated will result in even more drops to 14.41. On the upside, there is a resistance level at 15.68. A further resistance level may holdings at 16.21. The Relative Strength Index (RSI) on the 14-day chart is 28.66, which indicates oversold technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -4.33, which suggests price will go down in the next trading period. Percent R suggests that price movement has been low at 68.17%. Stochastics %K at 27.01% indicates the stock is a holding.
How much short interest is there in Bicycle Therapeutics Plc ADR?
A steep rise in short interest was recorded in Bicycle Therapeutics Plc ADR stocks on 2024-11-29, growing by 0.12 million shares to a total of 3.39 million shares. Yahoo Finance data shows the prior-month short interest on 2024-10-31 was 3.27 million shares. There was a rise of 3.64%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on August 31, 2022 when Cowen began covering the stock and recommended ‘”an Outperform”‘ rating .
